Author:
Peng Ting-wei,Ma Qing-feng,Li Jie,Wang Xue,Zhang Cong-hui,Ma Junwen,Li Jun-yi,Wang Wei,Zhu Cheng-liang,Liu Xing-hui
Abstract
AbstractChronic hepatitis B virus (HBV) infection is a major cause of hepatocellular carcinoma (HCC), pegylated-interferon-α(PEG-IFNα) and long-term nucleos(t)ide analogs (NUCs) are mainly drugs used to treat HBV infection, but the effectiveness is unsatisfactory in different populations, the exploration of novel therapeutic approaches is necessary. RAD51C is associated with DNA damage repair and plays an important role in the development and progression of tumors. Early cDNA microarray results showed that RAD51C expression was significantly increased in HBV-infected HCC cells, however, the relationship between HBV infection and abnormal expression of RAD51C has not been reported. Therefore, we conducted RT-PCR, western blot, Co-immunoprecipitation(Co-IP), and immunofluorescence(IF) to detect HBV-RAD51C interaction in RAD51C overexpression or interfering HCC cells. Our results showed that RAD51C and HBV X protein(HBX) produced a direct interaction in the nucleus, the HBV infection of HCC cells promoted RAD51C expression, and the increased expression of RAD51C promoted HBV replication. This indicated that RAD51C is closely related to the occurrence and development of HCC caused by HBV infection, and may bring a breakthrough in the the prevention and treatment study of HCC.
Funder
Natural Science Foundation of Hubei Province
Wuhan Municipal Health Research Foundation
Chinese foundation for the hepatitis prevention and control-TianQing liver disease research fund subject
Open Research Program of the State Key Laboratory of Virology of China
The Clinical Research Project of Health Industry of Shanghai Municipal Health Commission
Key Disciplines Group Construction Project of Pudong Health Bureau of Shanghai
Open Funds of Key Laboratory of Diagnosis and Treatment of Digestive System Tumors of Zhejiang Province
Publisher
Springer Science and Business Media LLC
Reference29 articles.
1. Tu, T. et al. A novel method to precisely quantify hepatitis B virus covalently closed circular (ccc)DNA formation and maintenance. Antiviral Res. 181, 104865 (2020).
2. Kim, J. et al. Ca2+/Calmodulin-dependent protein kinase II inhibits hepatitis B virus replication from cccDNA via AMPK activation and AKT/mTOR suppression. Microorganisms 10, 498 (2022).
3. Sevic, I., Elizalde, M. M., González López Ledesma, M. M., Flichman, D. M. & Campos, R. H. Analysis of fitness differences of hepatitis B virus genotypes D and F using a cotransfection assay. Arch. Virol. 164, 447–455 (2019).
4. Qin, Y. F. et al. Hepatitis B virus surface antigen promotes stemness of hepatocellular carcinoma through regulating MicroRNA-203a. J. Clin. Transl. Hepatol. 11, 118–129 (2023).
5. WHO. Hepatitis b, fact sheet. Geneva, Switzerland: WHO. https://www.who.int/news-room/fact-sheets/detail/hepatitis-b (2022).